2 Ideas For Yield Hunting In 2021, What I Added To The Watchlist

Dec. 29, 2020 9:00 AM ETABBV, VICI12 Comments
Steven Fiorillo profile picture
Steven Fiorillo


  • AbbVie and VICI Properties have earned a spot on my 2021 dividend watchlist which consists of companies I am considering adding to my dividend income portfolio.
  • AbbVie has a strong pipeline of medicines across Phase 1, 2, 3, and Submitted stages which should fuel future growth and generate additional income to its bottom line.
  • AbbVie operates in some of the most relevant categories as it is creating medicines to combat different types of cancers and diseases such as Parkinson's and Alzheimer's.
  • VICI Properties is a triple net lease REIT that collected 100% of their rents in 2020 and also increased their dividend to shareholders.

I am always on the lookout for dividend-paying companies to add to my portfolio. As 2020 comes to an end, I am overhauling my dividend watchlist for 2021. I found 2 companies I want to add to the income-producing side of my portfolio. This is where I take an attitude of if it doesn't have cash flow or pay a dividend, just say no. Currently, I am adding AbbVie (ABBV), and VICI Properties (VICI) to my 2021 dividend watchlist. I am sure there will be more but ABBV and VICI are catching my eye based on their financials, dividend aspects, and overall business operations. If you're looking to add some yield in 2021, these companies could be worth a look.

Why AbbVie's 5.03% dividend yield is catching my eye

Currently, I don't own big pharma stocks and this is a sector I would like to diversify into. ABBV is a specialty biopharmaceutical company that has a vast portfolio of medicines with therapeutic focuses on immunology, oncology, neuroscience, eye care, virology, and aesthetics. ABBV has a huge pipeline of medicines across the Phase 1, 2, 3 and submitted stages which should generate large amounts of revenue and cash flow in the future. For example, in immunology, ABBV-154 and ABBV-3373 are for rheumatoid arthritis and they are in Phase 2. In neuroscience, ABBV has ABBV-8E12 in Phase 2 and AL002 and AL003 in Phase 1 for Alzheimer's disease while having ABBV-951 in Phase 3 for Parkinson's disease. The oncology division at ABBV has many promising medicines in the pipeline from ABBV-011 for small cell lung cancer in Phase 1 to Veliparib in stage 3 for ovarian cancer, breast cancer, and lung cancer.

Table Description automatically generated

(Source: AbbVie)

ABBV's financials are aces in my book. For the trailing twelve months (TTM), ABBV has generated $40.65 billion in revenue, $28 billion in

This article was written by

Steven Fiorillo profile picture
I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking Alpha or https://dividendincomestreams.substack.com/

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Disclaimer: I am not an investment advisor or professional. This article is my own personal opinion and is not meant to be a recommendation of the purchase or sale of stock. Investors should conduct their own research before investing to see if the companies discussed in this article fits into their portfolio parameters

Recommended For You

Comments (12)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.